For selected patients with neurogenic bladder, sacral neuromodulation (SNM) treatment response is first evaluated during a temporary stimulation phase. This assessment helps determine whether symptoms improve sufficiently to consider permanent implantation. For international patients, remote programming and continued follow-up can also support treatment management after returning home.
1. Assessing Treatment Response During the SNM Trial
The SNM trial period commonly lasts 7–14 days, depending on clinical circumstances and the treatment protocol.
During this period, clinicians assess:
- Changes in urinary urgency and frequency.
- Changes in urinary incontinence episodes.
- Changes in urinary retention and bladder emptying.
- Urinary symptom diary results.
- Urodynamic measurements and other relevant clinical findings.
A symptom improvement of 50% or more is commonly used as a reference when considering permanent implantation. This threshold supports clinical decision-making but does not guarantee long-term treatment success.
2. Treatment Outcomes for Neurogenic Bladder
Treatment outcomes should be assessed according to the patient's neurological condition and baseline bladder function.
Relevant evaluation areas include urinary leakage, difficulty emptying the bladder, urinary retention, and changes in bladder function. Post-void residual measurements and urodynamic findings may also be reviewed when clinically indicated.
SNM is not suitable for every patient with neurogenic bladder. Treatment eligibility depends on the underlying neurological condition, urinary symptoms, examination findings, and specialist assessment. Current adult clinical guidance advises against SNM for neurogenic lower urinary tract dysfunction associated with spinal cord injury or spina bifida.
3. Follow-Up After Permanent Implantation
After permanent implantation, clinicians can adjust stimulation parameters according to the patient's symptoms and treatment response.
Follow-up may involve reviewing urinary symptom changes, assessing bladder emptying and incontinence, and determining whether device programming needs adjustment.
Patients with new or worsening urinary symptoms or other complications may require further clinical assessment. Follow-up arrangements should reflect individual risk factors and treatment progress rather than relying on one fixed schedule.
4. Remote Programming and International Follow-Up
Returning to China for every routine device adjustment can be difficult for international patients.
Our center provides remote programming and follow-up arrangements for eligible SNM patients after they return home. Device settings can be adjusted remotely by the clinical team, allowing continued treatment management without requiring a return trip to China for routine programming.
Our international patient services also include remote medical record review, consultation, and ongoing communication. Annual check-ins can be arranged as part of continued support.
5. Request a Neurogenic Bladder Treatment Assessment
To discuss SNM treatment outcomes and follow-up arrangements, you can submit:
- Your neurological diagnosis and medical history.
- Current urinary symptoms and their duration.
- Previous treatments and their results.
- Available urodynamic reports and imaging.
- Previous SNM treatment or implantation records, if applicable.
Our team can review the available information and discuss potential treatment options, follow-up arrangements, and the next steps for medical assessment.
Individual treatment suitability and outcomes vary. Remote medical assessments are based on submitted records and do not replace an in-person diagnosis.
Hot Tags: neurogenic bladder treatment outcomes and follow-up, China, price, pricelist, quotation, cost, Congenital Spinal Dysraphism, Hydronephrosis, Intravesical Botulinum Toxin Therapy, neurogenic bladder management device, neurogenic bladder system, neurogenic lower urinary tract stimulation system

